Antimania drugs are used in the treatment of bipolar disorder, a type of mood disorder also called as manic depression or manic-depressive illness, where patient’s mood fluctuate from feeling depressed to feeling super charged or manic.
The most widely used medication for the treatment of acute mania include lithium, valproate & carbamazepine (antipsychotics), ziprasidone, aripiprazole & clozapine (atypical antipsychotics), and lorazepam (benzodiazepine). Additionally, for the treatment of prophylaxis of bipolar mood disorder, lithium carbonate and lithium citrate are mostly used. Carbamazepine reduces transmission of the nerve impulse in the brain, which in turn reduces severity of manic episodes. Moreover, carbamazepine can be used as alternative to lithium salts, when patients fails to respond to lithium. Furthermore, sometimes carbamazepine are used with the combination of lithium, when there is need of rapid control of acute mania.
Global Antimania Drugs Market Drivers
The global antimania drugs market is expected to witness significant growth over the forecast period, owing to growing prevalence of bipolar disorder, globally. For instance, according to the World Health Organization (WHO) 2019 report, around 45 million people get affected by bipolar disorder globally.
Moreover, cost effectiveness of drugs for the treatment of bipolar disorder is another factor that is expected to drive the global antimania drugs market growth over the forecast period. For instance, cost of olanzapine is US$ 153, while cost of lithium is US$ 16 per month.
Furthermore, increasing number of clinical trials of drug for the treatment of bipolar depression, which is expected to propel the global antimania drugs market growth over the forecast period. For instance, in July 2018, Lumateperone received positive results from the Phase 3 clinical trial (Study 401 and Study 404) for the treatment of bipolar depression, announced by Intra-Cellular Therapies, Inc. In both the trials (Study 401 and Study 404), Lumateperone was found safer and tolerable by patients.
Moreover, in October 2019, Psychiatry Consortium, which is a strategic collaboration of leading medical research charities and pharmaceutical companies to accelerate innovative drug discovery in psychiatric diseases, had announced to launch a novel drug project to address people with mental health conditions such as bipolar disorder, depression and other mental disorders.
Psychiatry Consortium is a pioneering collaboration between the pharmaceutical companies, healthcare companies as well as leading medical charities. Therefore, increasing initiatives by companies to support the novel drug project, which in turn, is expected to increase the launch of new drugs for treatment of patients with mental health condition such as bipolar disorder and hence drives the global antimania drugs market growth.
Global Antimania Drugs Market Restraints
However, side effects associated with lithium for the treatment of bipolar disorder is one of the major factors that is expected to restrain the global antimania drugs market growth over the forecast period. For instance, if patient takes overdose of lithium, it causes anorexia. Moreover, prolong use of lithium can damage body’s ability to respond properly to the hormone vasopressin and can result into diabetes insipidus.
Global Antimania Drugs Market Regional Analysis
North America is expected to hold the highest market share in global antimania drugs market, owing to factors such as increasing technological advancements such as BiAffect app by University of Illinois, Chicago that helps to facilitate accurate detection of a patient’s mood and mental state. For instance, in 2018, the University of Illinois, Chicago (UIC) launched BiAffect app, which helps to track manic disorder and depressive mood in the patient with biopolar disorder. Moreover, BiAffect app predict mood episodes by analyzing the stroke dynamics such as error and typing speed of the patient. Therefore, launch of BiAffect app is expected to drive demand of antimania drugs for the treatment of bipolar disorder.
Moreover, increasing approvals of drug such as Vraylar by U.S Food and Drug administration (FDA) for the treatment of bipolar disorder is another factor that is expected to boost global antimania drugs market growth. For instance, in May 2019, Allergan plc and Gedeon Richter Plc announced to receive the approval from the U.S Food Drug Administration for expanded use of Vraylar (cariprazine) in the treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults.
Among regions, Europe is expected to hold the second highest market share in global antimania drug market, owing to increasing launches of new drugs for the treatment of bipolar disorder in Europe. For instance, in September 2019, LATUDA, an atypical antipsychotic agent was launched by Sumitomo Dainippon Pharma Co., Ltd., in China. LATUDA is used for the treatment bipolar depression. Additionally, the National Medical Products Administration (NMPA) has granted import drug license for LATUDA drug in China.
Global Antimania Drugs Market Key Players
Key players operating in the global antimania market are Eli Lilly and Company, Sumitomo Dainippon Pharma Co., Ltd, Allergan plc, Xian Janssen Pharmaceutical Ltd, Pfizer Inc., Otsuka Pharmaceutical, Taro Pharmaceutical Industries Ltd, Apotex Inc., Teva Pharmaceutical Industries Ltd, and Torrent Pharmaceutical Ltd.
On the basis of drug, the global antimania drugs market is segmented into:
- Lithium Salts
- Valproic Acid
On the basis of distribution channel, the global antimania drugs market is segmented into:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
On the basis of region, the global antimania drugs market is segmented into:
- North America
- Latin America
- Middle East
- Asia Pacific